埃博拉病毒疫苗rVSV-ZEBOV的研究进展

Advances in Research on Ebola Virus Vaccine: rVSV-ZEBOV

埃博拉病毒被列为A类病原体,感染后可引起埃博拉出血热,具有高传染率和高致死率。研发安全有效的抗病毒疫苗迫在眉睫。目前正在研发的埃博拉病毒疫苗包括病毒载体疫苗、蛋白疫苗、DNA疫苗等,其中最有希望的是重组水疱性口炎病毒载体疫苗r VSV-ZEBOV。该疫苗在预防和治疗埃博拉出血热方面具有较高的安全性和有效性,有望在2018年上市。为了深入了解r VSV-ZEBOV疫苗,现主要从制备方法、药理学研究和作用机制等方面对该疫苗进行介绍。

Ebola viruses are the causative agents of Ebola hemorrhagic fever with high infection rates and high fatality rates, which were classified as category A pathogens. A safe and effective vaccine against Ebola virus infection is urgently needed. Currently, the Ebola virus vaccine candidates under study include viral vectors vaccines, protein vaccines and DNA vaccines. Among them, the most promising vaccine candidate is the recombinant vesicular stomatitis viral vector-based vaccine： rVSV-ZEBOV. The vaccine is safe and effective in prevention and treatment Ebola hemorrhagic fever. It is expected to be available in 2018. In order to gain an in- depth understanding of rVSV-ZEBOV vaccine, the preparation, pharmacological studies, and mechanism of action of rVSV-ZEBOV vaccine are focused on.